An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer

[1]  J. Reis-Filho,et al.  Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment , 2010, Breast Cancer Research and Treatment.

[2]  P. Schirmacher,et al.  Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. , 2010, Human pathology.

[3]  D. Dabbs,et al.  Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy , 2010, Cancer.

[4]  Kornelia Polyak,et al.  Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer , 2010, Clinical Cancer Research.

[5]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[6]  L. Akslen,et al.  Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer , 2009, British Journal of Cancer.

[7]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[8]  T. Taguchi,et al.  Stem cell marker aldehyde dehydrogenase 1‐positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression , 2009, Cancer science.

[9]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[10]  S. Lakhani,et al.  Breast cancer stem cells: implications for therapy of breast cancer , 2008, Breast Cancer Research.

[11]  M. Ringnér,et al.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.

[12]  Max S Wicha,et al.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[14]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[15]  E. Winer,et al.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[17]  A. Buzdar.  Preoperative chemotherapy treatment of breast cancer—A review , 2007, Cancer.

[18]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[19]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Wachsmann-Hogiu,et al.  Spheres Isolated from 9L Gliosarcoma Rat Cell Line Possess Chemoresistant and Aggressive Cancer Stem‐Like Cells , 2007, Stem cells.

[21]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[22]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[23]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[24]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[25]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[26]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[29]  Roman Rouzier,et al.  Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[31]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[32]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[33]  Maria Athelogou,et al.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[35]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[36]  Alan Ashworth,et al.  Stem cells and breast cancer: A field in transit , 2003, Nature Reviews Cancer.

[37]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[39]  C. Osborne,et al.  Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[41]  W. Sikov.  Pathologic Complete Response in Breast Cancer Patients Receiving Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy: Evaluating the Effect of Race/Ethnicity , 2011 .

[42]  Harikrishna Nakshatri,et al.  Breast cancer stem cells and intrinsic subtypes: controversies rage on. , 2009, Current stem cell research & therapy.

[43]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[44]  P. Ellis,et al.  Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.